Diminished Disease-Free Survival After Lobectomy: Screening Implications

Area of Science:

• Thoracic surgery
• Pulmonary oncology
• Epidemiology

Background:

• Assessing the impact of lobectomy on life expectancy in healthy smokers is crucial for refining lung cancer screening strategies.
• Understanding the long-term outcomes of surgical intervention in this demographic is essential for patient counseling and healthcare policy.

Purpose of the Study:

• To estimate the effect of lobectomy on life expectancy in healthy smokers.
• To evaluate the implications of these findings for current lung cancer screening programs.

Main Methods:

• Retrospective cohort study of 261 patients with stage I non-small-cell lung cancer who underwent lobectomy.
• Analysis of lung cancer survival, all-cause survival, and fatality over a minimum of 15 years.
• Comparison of disease-free survival with actuarial life expectancy in the general US population.

Main Results:

• Five-year disease-free fatality was 16.1%, compared to 27.6% for lung cancer fatality.
• Disease-free survival was reduced by an average of 6.9 years, representing 41% of expected actuarial life expectancy.
• Survival divergence from expected norms became apparent primarily after 6 years post-surgery.

Conclusions:

• Lobectomy substantially decreases long-term disease-free survival in healthy smokers fit for surgery.
• In screened populations, the survival reduction in overdiagnosed individuals may counteract the mortality benefits of early lung cancer detection.
• These findings necessitate a re-evaluation of the risk-benefit balance in lung cancer screening for select patient groups.